Andrew Perry - Jan 3, 2023 Form 4 Insider Report for G1 Therapeutics, Inc. (GTHX)

Role
Chief Commercial Officer
Signature
/s/ James Stillman Hanson, attorney-in-fact
Stock symbol
GTHX
Transactions as of
Jan 3, 2023
Transactions value $
-$4,572
Form type
4
Date filed
1/5/2023, 07:25 PM
Previous filing
Jan 5, 2022
Next filing
May 12, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GTHX Common Stock Award $0 +16.1K +267.44% $0.00 22.1K Jan 3, 2023 Direct F1, F2, F3
transaction GTHX Common Stock Sale -$4.57K -820 -3.71% $5.58 21.3K Jan 4, 2023 Direct F4, F5, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GTHX Stock Options (Right to buy) Award $0 +32.1K $0.00 32.1K Jan 3, 2023 Common Stock 32.1K $5.73 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2024 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
F2 Each RSU represents a contingent right to receive one share of Issuer common stock.
F3 Represents (i) 20 shares of common stock; (ii) 6,000 RSUs from award granted on January 3, 2022; and (iii) 16,100 RSUs from award granted on January 3, 2023.
F4 The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person.
F5 The price represents the weighted average price with a low of $5.44 and a high of $5.78. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 Represents (i) 700 shares of common stock; (ii) 4,500 RSUs from award granted on January 3, 2022; and (iii) 16,100 RSUs from award granted on January 3, 2023.
F7 The shares underlying this option vest as to 25% of the shares on January 3, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.

Remarks:

Note: On January 3, 2023, the reporting person was also granted performance-based restricted stock units that are subject to material conditions beyond the reporting person's control, and, therefore, not considered derivative securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, and excluded from this report.